Scientists have announced a breakthrough in cancer treatment that could offer new hope for patients with hard-to-treat tumors. A newly developed targeted therapy has shown strong results in early clinical trials, shrinking tumors that previously responded poorly to conventional treatments.

The therapy uses precision medicine to identify specific genetic mutations inside cancer cells. Once detected, a specialized drug targets and disables those mutations, preventing cancer cells from multiplying.

Researchers say the treatment is particularly effective against aggressive cancers such as pancreatic, ovarian, and certain lung tumors. Unlike chemotherapy, the new therapy produces fewer side effects because it attacks only mutated cells rather than healthy tissue.

Patients in the trial experienced notable improvements in symptoms and quality of life. Some saw tumor reductions within weeks of treatment, generating optimism among oncologists.

However, larger clinical trials are still needed before regulatory approval. Scientists caution that while results are promising, long-term effectiveness and safety must be confirmed.

If approved, the therapy could mark a major milestone in precision oncology, offering patients new options for cancers that previously had limited treatment success.